Loading…
Clinical-stage biotech developing cancer immunotherapies targeting the WT1 tumor antigen for blood and solid cancers.
Clinical-stage biotech developing cancer immunotherapies targeting the WT1 tumor antigen for blood and solid cancers.
Has no product sales: it is funded by money raised from investors, so cash runway and each round of financing matter. Galinpepimut-S is its lead drug in a late-stage trial in acute myeloid leukaemia, where results decide whether it can seek approval or a partner.
Moat: none (IP / patents). Pre-revenue biotech; success depends entirely on unproven late-stage trial outcomes.
Headquarters: New York, New York, US · Founded: 2017 · Employees: 13
Size SELLAS Life Sciences (SLS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.70B, the 1904th largest of 3,117 United States companies the cockpit tracks. Shares closed at $8.42 on 6 Nov 2026.
Performance Over six months the shares gained 68.1%, against -10.6% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.00M |
| Revenue growth | — | — | — | -100% | — |
| Gross profit | $0 | $0 | $0 | $0 | $443,000 |
| EBITDA | -$35.2M | -$28.3M | -$31.5M | -$37.9M | -$31.5M |
| Net income | -$32.5M | -$26.9M | -$30.9M | -$37.3M | -$41.3M |
| Free cash flow | -$28.4M | -$28.4M | -$35.4M | -$36.9M | -$28.3M |
| Capital expenditure | $0 | $0 | $0 | $5.50M | $4.50M |
| Total debt | $737,000 | $1.00M | $1.00M | $906,000 | $945,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| SELLAS Life Sciences SLS | $1.70B | +68% | n/a | n/a | n/a | n/a |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
| Merck & MRK | $362B | +33% | +5% | 18% | 5.4× | 4.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SLS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -25.2% | -0.1% | 2nd lowest of 21 |
| 6-month return | +68.1% | -10.6% | 2nd highest of 20 |
| Distance from 52-week high | -47.0% | -31.6% | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SELLAS Life Sciences SLS | United States | $1.70B | +68% | n/a | n/a | n/a | n/a | n/a |
| Faes Farma FAE.MC | Spain | $1.71B | +5% | +32% | 14% | 2.6× | 3.1% | +9.9% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | 6.5× | 49.3% | +23.0% |
| Yifan Pharmaceutical 002019.SZ | China | $1.72B | -14% | -5% | 8% | 2.7× | n/a | n/a |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 4.5× | 15.3% | +19.0% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 4.7× | 6.7% | -4.3% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 1.2× | -6.0% | -5.6% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 2.2× | -15.1% | +13.5% |
| Cohance Lifesciences COHANCE.NS | India | $1.75B | -11% | +41% | 6% | 7.7× | n/a | n/a |
| Agios Pharmaceuticals AGIO | United States | $1.76B | +6% | +141% | -467% | 11.9× | n/a | n/a |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.76B | -25% | -13% | 12% | 5.9× | 14.7% | -14.0% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.77B | -11% | +7% | 39% | 9.4× | 19.5% | +10.8% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 2.2× | -4.5% | +6.8% |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 15.3× | 39.6% | +359.6% |
| PharmaResearch 214450.KS | South Korea | $1.79B | -25% | +34% | 39% | 3.5× | -14.2% | +37.6% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | 3.7× | -4.1% | +0.2% |
| Tsumura & 4540.T | Japan | $1.81B | +2% | +10% | 18% | 2.0× | n/a | n/a |
| Eris Lifesciences ERIS.NS | India | $1.82B | -11% | +11% | 26% | 5.8× | 24.7% | +20.9% |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | 18.4× | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 1.7× | n/a | n/a |